Medicago’s head office is located in Québec City, Québec, where the Corporation currently rents premises of approximately 16,000 square feet, of which approximately 9,000 square feet are used as office space and 7,000 square feet as a laboratory. The Corporation uses these premises for its administration, research and development activities.
Medicago owns a 14,000-square-foot pilot production facility located in the “Parc Technologique du Québec Métropolitain” in Québec City, Québec. This facility includes a greenhouse built to comply with cGMP standards, as well as an extraction/purification unit. Medicago has the option to acquire an adjacent property which will allow the Company to double the size of its current production facilities.
This high-tech greenhouse complex meets strict confinement standards (bio safety level 2+). In addition to a wind-resistant structure, concrete floor, sedimentation filtration system and internal condition controls, access to the greenhouse is controlled by an air-lock. External pollutants and insects are controlled by a series of screens designed to filter air moving in and out of the greenhouse. This pilot production facility was inaugurated in March 2005 and is believed to be the first and only one of its kind in the world.
Medicago rents another premises of approximately 13,000 square feet, of which approximately 6,000 square feet are used as office space, 7,000 square feet as a production and storage. The Company uses these premises for its quality assurance and quality control activities and downstream processing.
Medicago U.S.A., a wholly owned subsidiary of Medicago Inc., has completed the construction of its cGMP facility in Research Triangle Park (RTP), North Carolina. This Virus-Like-Particle plant-based vaccine facility includes a fully automated greenhouse and a state of the art extraction and purification unit. The 97,000-square-foot cGMP facility is targeted to produce 10 million doses of pandemic influenza vaccine per month. On an annual basis, the facility could have production capacity of 30 million doses of quadrivalent seasonal influenza vaccine or 120 million doses of pandemic influenza vaccine.